Skip to Content

Drug Interactions between MiraLAX and Senokot S

This report displays the potential drug interactions for the following 2 drugs:

  • MiraLAX (polyethylene glycol 3350)
  • Senokot S (docusate/senna)

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

senna polyethylene glycol 3350

Applies to: Senokot S (docusate / senna) and MiraLAX (polyethylene glycol 3350)

Using polyethylene glycol 3350 together with senna may increase the risk of gastrointestinal side effects such as ulcerations in the colon and ischemic colitis (an inflammatory condition caused by reduced blood flow to the colon due to narrowed or blocked blood vessels). Although these side effects are relatively rare, they may be potentially serous and life-threatening, particularly ischemic colitis. Nonetheless, certain bowel cleansing regimens given prior to a colonoscopy may require the concurrent use of a stimulant laxative such as senna in order to be fully effective. You should avoid using these medications together unless specifically recommended or prescribed by your doctor. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

No interactions were found. This does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Stimulant and hyperosmotic laxatives

Therapeutic duplication

The recommended maximum number of medicines in the 'stimulant and hyperosmotic laxatives' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'stimulant and hyperosmotic laxatives' category:

  • MiraLAX (polyethylene glycol 3350)
  • Senokot S (docusate/senna)

Note: The benefits of taking this combination of medicines may outweigh any risks associated with therapeutic duplication. This information does not take the place of talking to your doctor. Always check with your healthcare provider to determine if any adjustments to your medications are needed.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.